ARKG: I'm Holding Off Buying For These 3 Reasons

28.08.2025 08:25

See why ARK Genomic Revolution ETF faces challenges with unprofitable holdings, high costs, & limited treatment approvals despite growth. Click for my ARKG update.

Read More

Scenic Enters License and Research Agreement with Alnylam

26.08.2025 09:00

Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. "Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets

Read More

Leaders Come Together to Advance the Industry at Veeva Summit

21.08.2025 11:03

Veeva Systems (NYSE: VEEV) today announced highlights of its upcoming Veeva R&D and Quality Summit, where leaders across life sciences and Veeva exchange impactful ideas and innovations. BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer are among the leaders coming together September 3-4 in Boston to share how they are advancing clinical, regulatory, safety, and quality.

Read More

Private Credit Is a Booming Business. Where One Pro Sees Risks and Opportunities Now.

14.08.2025 06:00

Brad Marshall, global head of private credit strategies at Blackstone, says he owes his family and career to this asset class. How he manages default risk.

Read More

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock

11.08.2025 14:30

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Buy” opinion via Barchart. The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025. Analyst sentiment is mostly bullish with high price targets....

Read More

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock

11.08.2025 13:00

Many Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders ditched their stock over the past year, which may be of...

Read More

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

11.08.2025 12:00

CAMBRIDGE, Mass., August 11, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular disease

Read More

Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls

04.08.2025 13:35

Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls

Read More

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

31.07.2025 16:47

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsChristine Regan Akinc - Chief...

Read More

Alnylam: Amvuttra Is Just Getting Started

31.07.2025 15:13

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR amyloidosis. Click for my ALNY earnings update.

Read More

Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

31.07.2025 14:30

The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates

31.07.2025 13:15

Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Read More

Alnylam: Q2 Earnings Snapshot

31.07.2025 12:18

CAMBRIDGE, Mass. AP) — Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported a loss of $66.3 million in its second quarter.

Read More

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

31.07.2025 12:00

CAMBRIDGE, Mass., July 31, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights.

Read More

Alnylam Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

31.07.2025 11:34

Read More

Exploring Three High Growth Tech Stocks In The US Market

22.07.2025 17:38

As the S&P 500 and Nasdaq Composite recently retreated from record highs amid a deluge of earnings reports, investors are closely watching how major tech stocks will perform in this dynamic environment. In such a climate, identifying high-growth tech stocks involves looking for companies with strong earnings potential and innovative capabilities that can thrive despite broader market fluctuations.

Read More

Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock?

22.07.2025 16:00

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More

Exploring 3 High Growth Tech Stocks In The US Market

02.07.2025 11:38

The United States market has shown a positive trajectory, climbing 2.9% in the last week and up 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this context of robust market performance, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation within this dynamic sector.

Read More

Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) dropped from Russell Midcap Value Index

30.06.2025 13:10

Alnylam Pharmaceuticals, Inc. dropped from Russell Midcap Value Index...

Read More

Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) dropped from Russell 3000 Value Index

30.06.2025 13:07

Alnylam Pharmaceuticals, Inc. dropped from Russell 3000 Value Index...

Read More